Bruker Co. (NASDAQ:BRKR) Receives $79.36 Consensus Price Target from Brokerages

Shares of Bruker Co. (NASDAQ:BRKR - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the eleven ratings firms that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have given a hold recommendation and seven have given a buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $79.36.

Several analysts have commented on BRKR shares. Citigroup decreased their price target on shares of Bruker from $80.00 to $75.00 and set a "buy" rating on the stock in a research note on Wednesday. Wolfe Research downgraded Bruker from an "outperform" rating to a "peer perform" rating in a research report on Monday, September 30th. Barclays dropped their price target on Bruker from $75.00 to $69.00 and set an "overweight" rating for the company in a research note on Wednesday. TD Cowen reduced their price objective on Bruker from $72.00 to $70.00 and set a "hold" rating on the stock in a research note on Wednesday. Finally, Wells Fargo & Company lowered their price objective on shares of Bruker from $78.00 to $75.00 and set an "overweight" rating for the company in a research report on Wednesday.

Bruker Price Performance

Shares of NASDAQ BRKR traded down $2.76 during mid-day trading on Friday, reaching $57.73. The company's stock had a trading volume of 1,077,381 shares, compared to its average volume of 1,072,928. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.65 and a quick ratio of 0.75. Bruker has a 52 week low of $54.55 and a 52 week high of $94.86. The stock has a fifty day moving average of $63.83 and a two-hundred day moving average of $66.47. The firm has a market capitalization of $8.74 billion, a PE ratio of 23.95, a P/E/G ratio of 2.32 and a beta of 1.20.

Bruker (NASDAQ:BRKR - Get Free Report) last announced its quarterly earnings data on Tuesday, November 5th. The medical research company reported $0.60 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.61 by ($0.01). Bruker had a net margin of 11.29% and a return on equity of 24.92%. The company had revenue of $864.40 million for the quarter, compared to analysts' expectations of $866.46 million. During the same period last year, the business earned $0.74 earnings per share. The company's quarterly revenue was up 16.4% compared to the same quarter last year. As a group, sell-side analysts anticipate that Bruker will post 2.61 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in BRKR. First Horizon Advisors Inc. lifted its position in Bruker by 120.4% during the second quarter. First Horizon Advisors Inc. now owns 399 shares of the medical research company's stock valued at $25,000 after acquiring an additional 218 shares during the last quarter. Covestor Ltd lifted its holdings in shares of Bruker by 139.1% during the 1st quarter. Covestor Ltd now owns 361 shares of the medical research company's stock valued at $34,000 after purchasing an additional 210 shares during the last quarter. UMB Bank n.a. boosted its position in shares of Bruker by 115.3% in the 3rd quarter. UMB Bank n.a. now owns 661 shares of the medical research company's stock worth $46,000 after purchasing an additional 354 shares in the last quarter. Gordian Capital Singapore Pte Ltd acquired a new position in Bruker during the 2nd quarter valued at about $52,000. Finally, GAMMA Investing LLC increased its position in Bruker by 81.0% during the 3rd quarter. GAMMA Investing LLC now owns 867 shares of the medical research company's stock valued at $60,000 after buying an additional 388 shares in the last quarter. 79.52% of the stock is currently owned by hedge funds and other institutional investors.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.